As cannabis legalization spreads across the globe, another mind-altering drug is trying to follow in its tracks: magic mushrooms.
Denver voted in May to decriminalize the fungus that contains psilocybin, a psychedelic compound popularized by ’60s counterculture. Oakland, Calif. followed Denver’s lead a few weeks later and Oregon is trying to get a similar measure on the ballot for 2020.
Advocates say mushrooms have untapped medical potential that could be as big as cannabis, particularly for treating depression and addiction. The U.S. Food and Drug Administration granted “breakthrough therapy” status in October to Compass Pathways Ltd. to test the drug for treatment-resistant depression, expediting the development process. The London-based company says it’s now proceeding with a large-scale clinical trial in Europe and North America.